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To the Editor: The Gauging Albuminuria Reduction With
Lotrel in Diabetic Patients With Hypertension (GUARD)
study,1 showed that combination of an angiotensin-convert-
ing enzyme inhibitor (ACEi) with a diuretic significantly
reduced albuminuria more than combination with a calcium
channel blocker in patients with type 2 diabetes. As blood
pressure (BP) is lowered more in combining an ACEi with a
calcium channel blocker, the marked antiproteinuric effects
of combining an ACEi with a diuretic cannot be explained by
BP control. Thus, at least to reduce proteinuria, a diuretic
rather than a calcium channel blocker should be combined
with an ACEi or inhibitors of the renin–angiotensin system
(RAS).
In contrast to albuminuria reduction, the decline in the
glomerular filtration rate (GFR) from the baseline to the end of
the 1-year GUARD1 study was much smaller when an ACEi
was combined with a calcium channel blocker than with
diuretic. Although this finding is often considered unfavorable
for diuretics, we think it opposite. Diuretics suppress tubular
sodium reabsorption, making urinary sodium excretion greater
than intake. As far as BP, glomerular capillary pressure, GFR,
and tubular sodium load remain at the baseline levels, and
sodium balance continues negative, resulting in fall in BP. Once
BP is lowered, glomerular capillary pressure is also lowered,
leading to reductions in both GFR and tubular sodium load.
Under diuretic administration, a steady state of sodium balance
can be achieved only when the GFR and tubular sodium load
are reduced.2 We believe that the decline in GFR in diuretics
reflects lowered glomerular capillary pressure as seen with
renin–angiotensin system inhibitors,3 and therefore may suggest
long-term renoprotection. Diuretics should be used as the
second-line antihypertensive agent for proteinuric patients with
chronic kidney disease, in combination with renin–angiotensin
system inhibitors to reduce proteinuria and to preserve renal
function.
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Current guidelines support the notion that patients with
proteinuric kidney disease should receive a thiazide
diuretic as a second agent, if further blood pressure
reduction is needed.2 There are many studies where
addition of a nondihydropyridine calcium antagonist, that
is, diltiazem provided similar levels of blood pressure
reduction to hydrochlorothiazide. Use of this subclass of
calcium antagonists is also recommended by current
guidelines to reduce blood pressure and proteinuria.2–4
However, in patients with low levels of proteinuria, that is,
generally less than 1 g/day use of any calcium antagonist in
the presence of a blocker of the renin–angiotensin system
can reduce proteinuria.5 The Gauging Albuminuria Re-
duction With Lotrel in Diabetics With Hypertension
(GUARD) Study tested the hypothesis that a fixed-dose
combination of amlodipine/benazepril is more efficacious
in lowering proteinuria than a benazepril/hydrochlorothia-
zide combination.6 Although blood pressure was reduced to a
greater extent with amlodipine/benazepril, proteinuria was
reduced more by benazepril/hydrochlorothiazide. This
study is an example where using a surrogate marker effect
is misleading. A careful look at the data demonstrates that
a significantly greater fall in glomerular filtration rate
resulted in a relatively greater fall in proteinuria in the
benazepril/hydrochlorothiazide group. Given the better
blood pressure reduction without a fall in glomerular
filtration rate in the amlodipine/benazepril group, one
would have to argue for a calcium antagonist as a second-
line agent unless there was a compelling indication for a
diuretic, such as edema or volume overload. In short,
both thiazide diuretics and calcium antagonists get
blood pressure to goal and reduce proteinuria on back-
ground therapy that blocks the renin–angiotensin system,
so either is a viable option depending on the clinical
circumstance.
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